
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Head and Neck Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1536063
This article is part of the Research Topic New molecular pathways in thyroid biology: Role of coding and noncoding genes in thyroid pathophysiology, volume II View all 7 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
AbstractBackground: Cervical lymph node metastasis is a major factor influencing recurrence after surgery for papillary thyroid cancer. Molecular markers that can predict the presence of lymph node metastasis and assess the aggressiveness of papillary thyroid microcarcinoma (PTMC) remain poorly understood. The research question addressed whether specific genes, such as thrombospondin-4 (THBS4), could serve as predictive biomarkers for guiding surgical strategies, particularly in cases where current imaging modalities fail to detect LNM in the central region, and the decision for prophylactic central neck dissection remains controversial.Methods: Transcriptome sequencing was employed to screen for differentially expressed genes and perform enrichment analysis. The study defined two groups of PTMC patients: LNM(n=50) and NLNM(n=50). 10 samples from each group were used for transcriptome sequencing. The expression of THBS4 was evaluated in both groups. Additionally, the correlation between THBS4 expression and cancer-associated fibroblasts (CAFs), specifically the PDGFRA+ inflammatory CAFs, was investigated to understand the stromal regulatory protein's role in PTMC aggressiveness.Results: The analysis of sequencing data revealed that THBS4 expression was significantly higher in LNM PTMC compared to the NLNM group (Fold Change > 1.6 and P < 0.05). LNM PTMCs were also associated with a higher presence of PDGFRA+ inflammatory CAFs (P < 0.05), while no significant difference in the quantity of SMA+ myofibroblastic CAFs was observed between the two groups(P>0.05). Immunohistochemical analysis demonstrated increased THBS4(P < 0.01) and PDGFRA(P < 0.001) expression in LNM groups, while SMA staining showed no significant intergroup differences(P>0.05).Conclusion: This study's findings indicate that THBS4 could be a potential biomarker for predicting the risk of lymph node metastasis in papillary thyroid microcarcinoma, thus potentially guiding more personalized surgical interventions. Further validation in larger patient cohorts and the interactions between THBS4 and CAFs are necessary.
Keywords: papillary thyroid microcarcinoma, Tumor immune microenvironment, Thrombospondin-4, lymph node metastasis, Cancer-associated fibroblasts subsets
Received: 28 Nov 2024; Accepted: 26 Mar 2025.
Copyright: © 2025 Hu, Lin, Zheng, Wan, Zhao, Ma and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
JianMin Li, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.